Can Mouth Infection Bring Up Blood Pressure

Keys to understanding the law of prepaid

rejection is prevented members by age or preexisting conditions; standard shafts

THE NATION Photo / Marcelo Gomez

The law governing the prepaid system was approved yesterday by a large majority in Congress. Originally voted in the House of Representatives unanimously and amended in the Senate this year with the agreement of all blocks, yesterday won 190 votes in favor, none against and 29 abstentions mostly members of Pro and the Civic Coalition (CC).

The reform provides new benefits for users, but is strongly opposed by the largest companies in the sector.

In 31 articles, the law introduces the following modifications:

• obliges companies to cover medical insurance plans of care, the Compulsory Medical Plan (PMO) and the system with basic services for people with disabilities.

The

• benefits companies may not be less than the PMO.

• performance contracts must be approved by the Ministry of Health, and users can terminate them at any time.

• Age can not be a litmus test for admissions.

• Companies can not refuse membership to people with preexisting conditions, but applying differential values \u200b\u200bproperly justified and approved.

• Those over 65 years, ten years old in coverage, they can not increase the quota.

• mechanisms to be imposed from the government authorizing or not the increase in quotas.

• contracts between companies and users can not include periods of absence or wait for those features that are included in the PMO.

Best Highlights For Damaged Hair

Free workshop on low vision

Directed patients with macular diseases, family and friends, the ophthalmology department of the Hospital Italiano de Buenos Aires organized a free workshop on low vision. It can converse with specialists. The appointment will be on 13 May at 17, Potosí 4296, Capital. Information and registration: (011) 4959-0348, or email @ hospitalitaliano.org.a informes.docencia

List Of Bachelors Trips

Novartis says study shows Lucentis is safer than

Swiss drugmaker Novartis AG said Wednesday that a new study shows that its ophthalmic drug Lucentis is safer than Avastin cancer drug for the treatment of macular degeneration.

Novartis said the analysis conducted by the Johns Hopkins University represents the best available information from the comparison of Roche's Avastin and Lucentis.

"These data contribute to the existing body of evidence suggests that the risk of death and cerebrovascular accident (CVA) would be greater in patients treated with Avastin compared to Lucentis," said Novartis.

Novartis and its partner Roche generated each about 1,500 million dollars in sales last year with Lucentis, and some analysts believe could become a drug in excess of 10,000 million dollars sales.

"Now more than ever it is clear that Lucentis and Avastin are different, and Novartis believes that Lucentis is the best therapy for patients," said Trevor Mundel, head of global development at Novartis Pharma.

Last week, U.S. researchers reported on a study by the National Eye Institute that Avastin worked just as Lucentis in treating vision loss caused by macular degeneration, but had more side effects.

The results were considered a threat to the millions of dollars from sales of Lucentis they hope to collect Roche, which sells the medicine in the United States, and Novartis, which markets the rest of the world, since most doctors prefer Avastin, which is much cheaper.

Avastin costs $ 50 per injection, compared with nearly $ 2,000 it costs to Lucentis.

But doctors still hesitate to prescribe Avastin after a study showed higher rates of severe systemic side effects, which require hospitalization.

Christian Wedding Invitations Wording In Spanish

Avastin Avastin is as good as Lucentis to treat wet macular degeneration.

The results of the National Eye Institute study were released a week ago. The study, "Comparison of age-related macular degeneration treatment trials (CATT) "compared the two drugs head to head in a year long study in which about 1200 patients.

The study is important because Lucentis and Avastin are produced by the same company, Genentech. Lucentis is approved by the FDA for the treatment of wet macular degeneration, however, Avastin is the standard of care.

Lucentis has costs of 40 to 50 times more than Avastin.

In short, most retina specialists in the United States have been using the cheaper alternative as we have suspected that the two are equally effective in treating the disease, but at a fraction of the cost.

The CATT report compared the two injections in a variety of dosing schedules every four weeks versus "as needed." The results indicate that the two drugs are equally effective whether given regularly or as needed. "

The main difference between the two drugs is cost. Lucentis costs $ 2000, while Avastin is approximately $ 50 or less. Avastin is not sold directly to ophthalmologists by Genetech. capitalization pharmacies buy drugs, a chemotherapy agent, and divide it into smaller portions for injection for our use.

side effects of both drugs were similar. Both seem to be very confident after a year of study. Patients will be followed by more data on long-term security.

What does this mean?
This may be the end to the dispute between Avastin vs. Lucentis.
Finally, there is evidence that confirms what many of us have been suspecting ... cheaper drug is as good as the more expensive drug!
The economic impact of this study will be powerful.
Better yet, the study showed that the administration "as needed" may be as good as a regimented therapy regular dosing every 4-6 weeks.

"Randy" Randall V.
Wong, MD
Ophthalmologist, retina specialist
Fairfax, Virginia
http://www.retinaeyedoctor.com/

Randodry Patches On My Body

Why do not you shut up? New figures

Why is it so difficult for sellers to curb their language and remain silent?

The best salespeople know the importance of using the silence during a sales conversation. Here are six situations in which they should remain silent in a sales conversation:

1. Immediately after the customer asked a question.
2. When a client expresses an objection.
3. After asking the customer to buy.
4. When it seems that the customer has something to say.
5. When you realize you are talking too much about the features of your product.
6. After having provided a considerable amount information to process.

Watch out for these situations in future meetings or sales calls. When they occur, stop talking and start listening.

Does Preparation H Work On Stomach

fear for the future of stem cell therapies

A ban would jeopardize the development of therapies for previously incurable diseases.

Developing treatments Embryonic stem cells could be put at risk if they prohibit the patenting of such procedures in Europe, scientists warn.

In a letter published in the journal Nature , researchers from different countries expressed "deep concern" over the next ruling of the Court of Justice of the European Union (EU) over whether to allow patent protection embryonic stem cell lines.

Related Stories
• unpublished stem cell treatment against stroke
• , 2010 Medical advances
• stem cell transplantation for blindness

Scientists say a ban will threaten the nascent bioscience industry that "promises to revolutionize the twenty-first century medicine."

The root of the debate are the embryos from which stem cells.

The attorney general of the Court, Judge Yves Bot, presented an opinion in which he declared it was "immoral to patent inventions based on research involving human embryo destruction."

Although the body is not obliged to support the opinion, often does.

"Without incentives"

Embryonic stem cells have the potential to become any body tissue.

Many scientists are very excited about the possibility of using them to create healthy cells to replace diseased tissue.

After more than a decade of research in the United States, where patent-yes there are already conducting clinical trials with these therapies.

" would be devastating for the court to support this opinion. Would jeopardize the future of biomedical research in Europe, and some projects here collapse"

Prof. Austin Smith, Wellcome Trust Centre for Stem Cell Research

In the letter published in Nature , scientists argue that the industry would have no incentive to do research in this field unless their innovations can be protected with patents.

One of the signatories is Professor Austin Smith, Wellcome Trust Centre for Stem Cell Research in Cambridge, England.

"would be devastating for the court to support this opinion. Would jeopardize the future of biomedical research in Europe, and some projects would collapse here," says Smith.

"This would also send the message that scientists are engaged in an immoral activity, so it would be very negative for our community and erode public confidence in what we do," he adds.

Professor Smith says that currently has over 100 lines of embryonic stem cells can be maintained indefinitely, so that concerns about potential commercialization of the human embryo "are inappropriate."

Another signatory, Professor Pete Coffey, director of the London Project to Cure Blindness, says there is "an ethical need to treat diseases" and, applying the ban on patenting, Europe will lose its place as leader in this field of research. Patent

past and future

In U.S. carried out trials with stem cell treatments.

Professor Coffey's team hopes to carry out clinical trials next year of a stem cell treatment for a form of blindness.

The case before the European Court was opened by the environmental organization Greenpeace, Germany.

As stated one of his advisers, Dr. Christoph Then, Greenpeace is not opposed to all research stem cell.

"We do not believe that the general counsel's opinion is very clear."

"Our original proposal was to clarify the patent law, especially regarding the industrial use of embryos," said Then.

is expected that the 13 judges of the Court of Justice of the EU consider the reasoning of Judge Yves Bot in the coming weeks and reach a decision within the next six months on whether to permit or prohibit the patenting past and future bioscience industry.